Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.56 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 5/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | SCTR | P47872 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21967428 | 0.91 | FLT3 (0.57) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967350 | 0.91 | FLT3 (0.51) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967679 | 0.90 | FLT3 (0.56) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967498 | 0.90 | FLT3 (0.69) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967225 | 0.90 | YTHDC1 (0.57) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967789 | 0.90 | FLT3 (0.56) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967649 | 0.89 | FLT3 (0.49) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967755 | 0.89 | FLT3 (0.49) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967125 | 0.89 | FLT3 (0.56) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967855 | 0.89 | FLT3 (0.55) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-26 | — | — | US | disclosed |
| EP-3233860-B1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIV PALACKEHO (CZ) | 2020-01-29 | — | — | EP | disclosed |
| US-20170342072-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-30 | — | — | US | disclosed |
| EP-3233860-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | Univerzita Palackého V Olomouci (CZ) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095881-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | TPMT, MTAP, ATIC | FLT3 2877/4885YTHDC1 384/4885NPC1 3926/4885 |
| US-20170342072-A1 | SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS | TPMT, MTAP, ATIC | FLT3 2877/4885YTHDC1 384/4885NPC1 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.